CULVER CITY, CA, Thursday October 1, 2009 – Sofie Biosciences, a molecular imaging company focused on next generation PET technologies, launched its GENISYS system last week at the 2009 World Molecular Imaging Congress in Montreal.
PET continues to be one of the fastest growing techniques in imaging with widespread adoption into preclinical research. GENISYS is not just another high performance preclinical PET system; it’s a novel class of PET imaging designed for a new generation of user.
Investigators from biology and medicine are looking for a research tool that provides an in vivo assay to compliment the wide array of in vitro assays. As a high throughput, benchtop PET system, GENISYS provides critical information with minimal infrastructure and cost. Turnkey installation and user-friendly operation mean GENISYS delivers in all University, biotech, and pharmaceutical settings. Integration of physiologic control with measurement output provides researcher’s with reproducible, quantitative information without the use of traditional, expensive hardware architectures. GENISYS is a valuable alternative to conventional preclinical systems.
“PET should be less complicated and available to anyone who wants to incorporate it into their research routine,” said Patrick Phelps, President & CEO, Sofie Biosciences. “Sofie worked closely with the UCLA Crump Institute to develop a next generation PET system that provides people with beautiful images and the output they desire, all within an imaging device that manages the health of your animal. I believe the GENISYS system meets a major unmet need in the maturing field of molecular imaging.”
Update: Please note that SOFIE no longer manufactures the GENISYS PET scanner. The updated product is the G4 PET/X-RAY.